Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study

BACKGROUND: OnabotulinumtoxinA is effective in treating chronic migraine (CM), but there are limited data assessing how allodynia affects preventive treatment responses. This subanalysis of the 108-week, multicenter, open-label COMPEL Study assessed the efficacy and safety of onabotulinumtoxinA in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Young, William B., Ivan Lopez, J., Rothrock, John F., Orejudos, Amelia, Manack Adams, Aubrey, Lipton, Richard B., Blumenfeld, Andrew M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734222/
https://www.ncbi.nlm.nih.gov/pubmed/30669961
http://dx.doi.org/10.1186/s10194-018-0952-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734222/
https://www.ncbi.nlm.nih.gov/pubmed/30669961
http://dx.doi.org/10.1186/s10194-018-0952-1

Ejemplares similares